Impact of rotor ablation in non-paroxysmal AF patients: Findings from the per-protocol population of the OASIS trial at long-term follow-up - 17/12/18

Abstract |
The objective of this study was to evaluate the long-term efficacy of FIRM ablation with PVAI vs PVAI plus posterior wall isolation (PWI) and non-PV trigger ablation in persistent (PeAF) and long-standing persistent AF (LSPAF) patients. The procedure time was recorded to be 180.6 ± 35.9 and 124.03 ± 45.4 minutes in the FIRM+PVI and PVI + PWI + non-PV trigger ablation group respectively. At 24-month follow-up, 24% (95% CI 8.7%–37.8%) in the FIRM-ablation group and 48% (95% CI 27.6–63.3%) in the non-PV trigger ablation group remained arrhythmia-free off-antiarrhythmic drugs after a single procedure.
Clinical Trial Registration: ClinicalTrials.gov (Identifier: NCT02533843).
Le texte complet de cet article est disponible en PDF.Plan
Disclosures: Dr. Di Biase is a consultant for Biosense Webster, Boston Scientific, Stereotaxis and St Jude Medical. Dr. Di Biase received speaker honoraria/travel from Medtronic, Atricure, EPiEP and Biotronik. Dr. Natale received speaker honorariums from Boston Scientific, Biosense Webster, St. Jude Medical, Biotronik and Medtronic, Dr Natale is a consultant for Biosense Webster, St Jude Medical and Janssen. Dr Burkhardt is a consultant for Biosense-Webster and Stereotaxis. All the remaining authors have no disclosures. |
Vol 205
P. 145-148 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?